Evidence map›Paper›PMID 38426765›Full record

ArticleMicrobiology spectrum2024

Human Vγ9Vδ2 T cells exhibit antifungal activity against

Satoru Koga, Takahiro Takazono, Hodaka Namie, Daisuke Okuno, Yuya Ito, Nana Nakada, Tatsuro Hirayama, Kazuaki Takeda, Shotaro Ide, Naoki Iwanaga and 7 more

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Pathogenesis and Triazole Resistance inInfection and drug resistance · 2026
    Review
  3. Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  4. Mgl2Nature communications · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Satoru KogaDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.ORCID 0009-0006-9415-2305
Takahiro TakazonoDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.ORCID 0000-0002-0696-5386
Hodaka NamieDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Daisuke OkunoDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Yuya ItoDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Nana NakadaDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Tatsuro HirayamaDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.ORCID 0000-0001-8554-3482
Kazuaki TakedaDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Shotaro IdeDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Naoki IwanagaDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Masato TashiroDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0001-7609-7679
Noriho SakamotoDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Akira WatanabeMedical Mycology Research Center, Chiba University, Chiba, Japan.ORCID 0000-0002-3057-2937
Koichi IzumikawaDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Katsunori YanagiharaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Yoshimasa TanakaCenter for Medical Innovation, Nagasaki University, Nagasaki, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Nagasaki University Hospital · JPNagasaki University · JPChiba University Hospital · JP

Funding

Japan Agency for Medical Research and Development (AMED) 22fk0108530h0001MEXT | Japan Society for the Promotion of Science (JSPS) 23K07941MEXT | Japan Society for the Promotion of Science (JSPS) A48MEXT | Japan Society for the Promotion of Science (JSPS) A90Ministry of Education, Culture, Sports, Science and Technology (MEXT) JPMJST2281Nagasaki University 16K08844Nagasaki University 23K06677
6 · The paper itself

Abstract

Invasive aspergillosis (IA) and mucormycosis are life-threatening diseases, especially among immunocompromised patients. Drug-resistant IMPORTANCE: Invasive aspergillosis (IA) and mucormycosis are often resistant to treatment with conventional antifungal agents and have a high mortality rate. Additionally, effective antifungal treatment is hindered by drug toxicity, given that both fungal and human cells are eukaryotic, and antifungal agents are also likely to act on human cells, resulting in adverse effects. Therefore, the development of novel therapeutic agents specifically targeting fungi is challenging. This study demonstrated the antifungal activity of Vγ9Vδ2 T cells against various

Indexed as

AspergillosisMucormycosisAntifungal AgentsAspergillusAspergillus fumigatusFungiHumansAntifungal Agentsfilamentous fungiinvasive aspergillosisnitrogen-containing bisphosphonate prodrugγδ T cell

Identifiers

PMID38426765
PMCPMC10986472
OpenAlexW4392386577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.